We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Immune Regulators Predict Severity of Plasmodium vivax Malaria

By LabMedica International staff writers
Posted on 17 Oct 2022

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. More...

In Plasmodium vivax infections, the uncontrolled production of these molecules is thought to contribute to pathogenesis and has been proposed as a possible predictor for disease complications.

Severe clinical manifestations described for P. vivax infections include neurological conditions, especially coma or successive seizures, and impaired consciousness; hematological conditions, in particular anemia, severe thrombocytopenia and hemoglobinuria; systemic symptoms, such as circulatory collapse, vital organ damage, including respiratory dysfunction and acute respiratory distress syndrome, acute kidney failure, splenic rupture, liver dysfunction, and jaundice.

Tropical Disease Specialists at the Universidad de Córdoba (Montería, Colombia) and their colleagues enrolled 156 participants in a study and classified them into three groups: 50 patients with severe malaria (SM), 56 non-severe malaria (NSM) and 50 healthy controls (HC), all from an endemic area. After confirming the diagnosis of P. vivax malaria by microscopy and molecular techniques; biochemical, hematological and parasitological parameters were determined.

Patients were classified as severe malaria if they met the criteria for any of the following complications: Hemoglobin concentration lower than 7 mg/dL was considered severe anemia, platelet concentration lower than 50.000 platelets/μL was considered severe thrombocytopenia, hypoglycemia (glucose < 60mg/dL), creatinine concentration higher than 1.3 mg/dL was considered indicative of renal dysfunction, Glutamic-pyruvic transaminase (GPT), Glutamic-oxaloacetic transaminase (GOT) concentration higher than 40 u/L was considered hepatic dysfunction.

IL-4, IL-2, CXCL10 (IP-10), IL-1β, TNF-α, CCL2 (MCP-1), IL-17A, IL-6, IL-10, IFN-γ, IL-12p70, CXCL8 (IL-8), and active TGF-β1 determination was performed in plasma, using the Human Essential Immune Response Panel kit (13-plex) (Biolegend, San Diego, CA, USA). Samples were run in duplicates in a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA).

The scientists reported that the levels of several cytokines and chemokines, CXCL10, IL-10, IL-6, IL-4, CCL2 and IFN-γ were found to be significantly higher in severe, compared to non-severe P. vivax malaria patients. Severe thrombocytopenia was positively correlated with IL-4, CXCL10, IL-6, IL-10 and IFN-γ levels; renal dysfunction was related to an increase in IL-2, IL-1β, IL-17A and IL-8, and hepatic impairment with CXCL10, MCP-1, IL-6 and IFN-γ. A Lasso regression model suggests that IL-4, IL-10, CCL2 and TGF-β might be developed as biomarkers for severity in P. vivax malaria.

The authors concluded that their study showed that there is a differential concentration of some cytokines and chemokines between patients with non-severe malaria and severe P. vivax malaria; and that there are associations between these molecules with manifestations that occur in severe malaria. Four molecules with potential to become biomarkers of severity were identified. The study was published on September 30, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Universidad de Córdoba 
Biolegend 
Becton Dickinson 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.